Ranbaxy, Arrow Face EC Fines For Pay-For-Delay Deals
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and New Zealand's Arrow Pharmaceuticals are among nine international drug makers that face European Commission antitrust fine involving pay-for-delay deals to slow introduction of generic drugs.